Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer

Julie Decock, N. Obermajer, S. Vozelj, Wouter R. Hendrickx, R. Paridaens, J. Kos

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Numerous studies have linked cathepsins and their inhibitor cystatin C to tumor invasion and metastasis. We examined whether cathepsin B, cathepsin H, cathepsin X and cystatin C could be detected in sera from women with early-stage or inflammatory breast cancer and whether they correlated with clinicopathological characteristics. Preoperative serum was obtained from 176 patients with early-stage breast cancer (tumor size ≤5 cm, negative lymph nodes) and 31 patients with inflammatory breast cancer. Cathepsin and cystatin C levels were measured by ELISA. The patient and tumor characteristics under study were age at diagnosis, menopausal status, tumor size, tumor grade, and steroid hormone receptor status. Serum cathepsin B levels were significantly lower in patients with poorly differentiated tumors. High cystatin C levels were associated with tumor size, postmenopausal status and patient age. Interestingly, significantly lower levels of cathepsin X and H were found in patients with inflammatory breast cancer, a trend also observed for cathepsin B and cystatin C. In conclusion, our results show a limited association of cathepsins B, H, X and cystatin C with established prognostic parameters. These data are promising and encourage future analysis of the clinical outcome of our patients in order to examine the potential prognostic value of these biomarkers. Further, this study indicates a role for cathepsin X and H in inflammatory breast cancer.

Original languageEnglish
Pages (from-to)161-168
Number of pages8
JournalInternational Journal of Biological Markers
Volume23
Issue number3
Publication statusPublished - 1 Dec 2008
Externally publishedYes

Fingerprint

Cathepsin H
Cathepsin C
Inflammatory Breast Neoplasms
Cystatin C
Cathepsins
Cathepsin B
Tumors
Serum
Neoplasms
Steroid hormones
Breast Neoplasms
Steroid Receptors
Biomarkers
Lymph Nodes
Enzyme-Linked Immunosorbent Assay
Association reactions
Hormones
Neoplasm Metastasis

Keywords

  • Breast cancer
  • Cathepsin
  • Cystatin C
  • Inflammatory
  • Serum

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. / Decock, Julie; Obermajer, N.; Vozelj, S.; Hendrickx, Wouter R.; Paridaens, R.; Kos, J.

In: International Journal of Biological Markers, Vol. 23, No. 3, 01.12.2008, p. 161-168.

Research output: Contribution to journalArticle

@article{4d3233bfeeb446d1b33eab523eaebd04,
title = "Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer",
abstract = "Numerous studies have linked cathepsins and their inhibitor cystatin C to tumor invasion and metastasis. We examined whether cathepsin B, cathepsin H, cathepsin X and cystatin C could be detected in sera from women with early-stage or inflammatory breast cancer and whether they correlated with clinicopathological characteristics. Preoperative serum was obtained from 176 patients with early-stage breast cancer (tumor size ≤5 cm, negative lymph nodes) and 31 patients with inflammatory breast cancer. Cathepsin and cystatin C levels were measured by ELISA. The patient and tumor characteristics under study were age at diagnosis, menopausal status, tumor size, tumor grade, and steroid hormone receptor status. Serum cathepsin B levels were significantly lower in patients with poorly differentiated tumors. High cystatin C levels were associated with tumor size, postmenopausal status and patient age. Interestingly, significantly lower levels of cathepsin X and H were found in patients with inflammatory breast cancer, a trend also observed for cathepsin B and cystatin C. In conclusion, our results show a limited association of cathepsins B, H, X and cystatin C with established prognostic parameters. These data are promising and encourage future analysis of the clinical outcome of our patients in order to examine the potential prognostic value of these biomarkers. Further, this study indicates a role for cathepsin X and H in inflammatory breast cancer.",
keywords = "Breast cancer, Cathepsin, Cystatin C, Inflammatory, Serum",
author = "Julie Decock and N. Obermajer and S. Vozelj and Hendrickx, {Wouter R.} and R. Paridaens and J. Kos",
year = "2008",
month = "12",
day = "1",
language = "English",
volume = "23",
pages = "161--168",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing",
number = "3",

}

TY - JOUR

T1 - Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer

AU - Decock, Julie

AU - Obermajer, N.

AU - Vozelj, S.

AU - Hendrickx, Wouter R.

AU - Paridaens, R.

AU - Kos, J.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Numerous studies have linked cathepsins and their inhibitor cystatin C to tumor invasion and metastasis. We examined whether cathepsin B, cathepsin H, cathepsin X and cystatin C could be detected in sera from women with early-stage or inflammatory breast cancer and whether they correlated with clinicopathological characteristics. Preoperative serum was obtained from 176 patients with early-stage breast cancer (tumor size ≤5 cm, negative lymph nodes) and 31 patients with inflammatory breast cancer. Cathepsin and cystatin C levels were measured by ELISA. The patient and tumor characteristics under study were age at diagnosis, menopausal status, tumor size, tumor grade, and steroid hormone receptor status. Serum cathepsin B levels were significantly lower in patients with poorly differentiated tumors. High cystatin C levels were associated with tumor size, postmenopausal status and patient age. Interestingly, significantly lower levels of cathepsin X and H were found in patients with inflammatory breast cancer, a trend also observed for cathepsin B and cystatin C. In conclusion, our results show a limited association of cathepsins B, H, X and cystatin C with established prognostic parameters. These data are promising and encourage future analysis of the clinical outcome of our patients in order to examine the potential prognostic value of these biomarkers. Further, this study indicates a role for cathepsin X and H in inflammatory breast cancer.

AB - Numerous studies have linked cathepsins and their inhibitor cystatin C to tumor invasion and metastasis. We examined whether cathepsin B, cathepsin H, cathepsin X and cystatin C could be detected in sera from women with early-stage or inflammatory breast cancer and whether they correlated with clinicopathological characteristics. Preoperative serum was obtained from 176 patients with early-stage breast cancer (tumor size ≤5 cm, negative lymph nodes) and 31 patients with inflammatory breast cancer. Cathepsin and cystatin C levels were measured by ELISA. The patient and tumor characteristics under study were age at diagnosis, menopausal status, tumor size, tumor grade, and steroid hormone receptor status. Serum cathepsin B levels were significantly lower in patients with poorly differentiated tumors. High cystatin C levels were associated with tumor size, postmenopausal status and patient age. Interestingly, significantly lower levels of cathepsin X and H were found in patients with inflammatory breast cancer, a trend also observed for cathepsin B and cystatin C. In conclusion, our results show a limited association of cathepsins B, H, X and cystatin C with established prognostic parameters. These data are promising and encourage future analysis of the clinical outcome of our patients in order to examine the potential prognostic value of these biomarkers. Further, this study indicates a role for cathepsin X and H in inflammatory breast cancer.

KW - Breast cancer

KW - Cathepsin

KW - Cystatin C

KW - Inflammatory

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=58149383921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149383921&partnerID=8YFLogxK

M3 - Article

C2 - 18949742

AN - SCOPUS:58149383921

VL - 23

SP - 161

EP - 168

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 3

ER -